<?xml version="1.0" encoding="UTF-8"?>
<ref id="B41-pharmaceuticals-10-00084">
 <label>41.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bloniecki</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Aarsland</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Blennow</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Cummings</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Falahati</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Winblad</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Freund-Levi</surname>
    <given-names>Y.</given-names>
   </name>
  </person-group>
  <article-title>Effects of Risperidone and Galantamine Treatment on Alzheimerâ€™s Disease Biomarker Levels in Cerebrospinal Fluid</article-title>
  <source>J. Alzheimer's Dis.</source>
  <year>2017</year>
  <volume>57</volume>
  <fpage>387</fpage>
  <lpage>393</lpage>
  <pub-id pub-id-type="doi">10.3233/JAD-160758</pub-id>
  <?supplied-pmid 28269767?>
  <pub-id pub-id-type="pmid">28269767</pub-id>
 </element-citation>
</ref>
